Lipid changes after switch from tenofovir disoproxil fumarate to tenofovir alafenamide: a longitudinal cohort study

被引：0
|
作者：
Berger, F. [1 ]
Milinkovic, A. [2 ]
Arenas-Pinto, A. [3 ]
Mauss, S. [1 ]
机构：
[1] Ctr HIV & Hepatogastroenterol, HIV & Hepatogastroenterol, Dusseldorf, Germany
[2] Chelsea & Westminster Hosp, Dept HIV Med, London, England
[3] UCL, Inst Global Hlth, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P195
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years
    Huynh, Tung
    Bui, Delana MyAn
    Zhou, Tina Xiwen
    Hu, Ke-Qin
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (07)
  • [32] EFFECTS OF TENOFOVIR ALAFENAMIDE FUMARATE VERSUS TENOFOVIR DISOPROXIL FUMARATE ON SERUM LIPID PROFILES IN PATIENTS WITH CHRONIC HEPATITIS B
    Cao, Fei
    Fan, Tao
    Jiang, Xue
    Wang, Jian
    Xiong, Ye
    Zhang, Shaoqiu
    Zhang, Zhiyi
    Liu, Xingxiang
    Zhu, Chuanwu
    Li, Jie
    Huang, Rui
    Wu, Chao
    HEPATOLOGY, 2024, 80 : S298 - S298
  • [33] Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
    Cheng, Pin-Nan
    Feng, I-Cher
    Chen, Jyh-Jou
    Kuo, Hsing-Tao
    Lee, Pei-Lun
    Yu, Ming-Lung
    Chiu, Yen-Cheng
    Chiu, Hung-Chih
    Chien, Shih-Chieh
    Chen, Pei-Jer
    Liu, Chun-Jen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 230 - 238
  • [34] Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
    Kawuma, Aida N.
    Wasmann, Roeland E.
    Sinxadi, Phumla
    Sokhela, Simiso M.
    Chandiwana, Nomathemba
    Venter, Willem D. F.
    Wiesner, Lubbe
    Maartens, Gary
    Denti, Paolo
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 821 - 830
  • [35] Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
    Hermansson, Linn
    Yilmaz, Aylin
    Price, Richard W.
    Nilsson, Staffan
    McCallister, Scott
    Makadzange, Tariro
    Das, Moupali
    Zetterberg, Henrik
    Blennow, Kaj
    Gisslen, Magnus
    PLOS ONE, 2019, 14 (12):
  • [36] Atherosclerotic CVD risk profile of tenofovir alafenamide versus tenofovir disoproxil fumarate
    Huhn, G.
    Shamblaw, D.
    Baril, J. G.
    Baker, D.
    Ward, D.
    Guo, S.
    Haubrich, R.
    Nguyen-Cleary, T.
    McCallister, S.
    Das, M.
    ANTIVIRAL THERAPY, 2016, 21 : A45 - A45
  • [37] The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
    Squillace, Nicola
    Ricci, Elena
    Menzaghi, Barbara
    De Socio, Giuseppe Vittorio
    Passerini, Simone
    Martinelli, Canio
    Mameli, Maria Sabrina
    Maggi, Paolo
    Falasca, Katia
    Cordier, Laura
    Celesia, Benedetto Maurizio
    Salomoni, Elena
    Di Biagio, Antonio
    Pellicano, Giovanni Francesco
    Bonfanti, Paolo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5515 - 5520
  • [38] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, A.
    Hughes, S.
    Pozniak, A.
    HIV MEDICINE, 2018, 19 : S30 - S30
  • [39] Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting
    Kauppinen, Kai Juhani
    Kivela, Pia
    Sutinen, Jussi
    AIDS PATIENT CARE AND STDS, 2019, 33 (12) : 500 - 506
  • [40] Establishing the Mechanisms of Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) in Osteogenesis
    Lazcano, Itzel
    Patel, Niyati
    Finerty, Declan
    Ross, Ryan
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 355 - 355
12345